26U
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more
Market Cap & Net Worth: 26U (26U)
26U (F:26U) has a market capitalization of $125.02 Million (€121.79 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #38921 globally and #5404 in its home market, demonstrating a 26.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 26U's stock price €24.40 by its total outstanding shares 4991580 (4.99 Million).
26U Market Cap History: 2026 to 2026
26U's market capitalization history from 2026 to 2026. Data shows growth from $125.02 Million to $125.02 Million (0.00% CAGR).
26U Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 26U's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 26U by Market Capitalization
Companies near 26U in the global market cap rankings as of March 19, 2026.
Key companies related to 26U by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
26U Historical Marketcap From 2026 to 2026
Between 2026 and today, 26U's market cap moved from $125.02 Million to $ 125.02 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €125.02 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of 26U was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $125.02 Million USD |
| MoneyControl | $125.02 Million USD |
| MarketWatch | $125.02 Million USD |
| marketcap.company | $125.02 Million USD |
| Reuters | $125.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.